Identification of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Multivariate Predictors by Cui, Yue et al.
Identification of Conversion from Mild Cognitive
Impairment to Alzheimer’s Disease Using Multivariate
Predictors
Yue Cui
1., Bing Liu
2., Suhuai Luo
1, Xiantong Zhen
2, Ming Fan
2, Tao Liu
1,3,4, Wanlin Zhu
3,4, Mira Park
1,
Tianzi Jiang
2,5*, Jesse S. Jin
1*, the Alzheimer’s Disease Neuroimaging Initiative
¤
1School of Design, Communication and Information Technology, University of Newcastle, Newcastle, New South Wales, Australia, 2LIAMA Center for Computational
Medicine, National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, People’s Republic of China, 3Neuropsychiatric
Institute, Prince of Wales Hospital, Randwick, Sydney, New South Wales, Australia, 4Brain and Ageing Research Program, School of Psychiatry, University of New South
Wales, Sydney, New South Wales, Australia, 5Key Laboratory for NeuroInformation of Ministry of Education, School of Life Science and Technology, University of Electronic
Science and Technology of China, Chengdu, People’s Republic of China
Abstract
Prediction of conversion from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) is of major interest in AD
research. A large number of potential predictors have been proposed, with most investigations tending to examine one or a
set of related predictors. In this study, we simultaneously examined multiple features from different modalities of data,
including structural magnetic resonance imaging (MRI) morphometry, cerebrospinal fluid (CSF) biomarkers and
neuropsychological and functional measures (NMs), to explore an optimal set of predictors of conversion from MCI to
AD in an Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. After FreeSurfer-derived MRI feature extraction, CSF
and NM feature collection, feature selection was employed to choose optimal subsets of features from each modality.
Support vector machine (SVM) classifiers were then trained on normal control (NC) and AD participants. Testing was
conducted on MCIc (MCI individuals who have converted to AD within 24 months) and MCInc (MCI individuals who have
not converted to AD within 24 months) groups. Classification results demonstrated that NMs outperformed CSF and MRI
features. The combination of selected NM, MRI and CSF features attained an accuracy of 67.13%, a sensitivity of 96.43%, a
specificity of 48.28%, and an AUC (area under curve) of 0.796. Analysis of the predictive values of MCIc who converted at
different follow-up evaluations showed that the predictive values were significantly different between individuals who
converted within 12 months and after 12 months. This study establishes meaningful multivariate predictors composed of
selected NM, MRI and CSF measures which may be useful and practical for clinical diagnosis.
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Introduction
Mild cognitive impairment (MCI) has been conceptualized as
a disorder situated in the spectrum between normal cognition
and dementia. However, only a proportion of individuals with
MCI progress to dementia. Consequently, prediction of the like-
lihood of MCI individuals developing Alzheimer’s disease (AD)
is increasingly essential. Moreover, successful prediction offers the
opportunity for the enrichment of clinical trials of disease-
modifying therapies which aim to slow or prevent AD.
Presently, there are few clinical or imaging markers for the
early identification of MCI which progresses to AD and MCI
which does not progress. Based upon subsequent diagnosis status
at follow-up evaluations, MCI participants can be divided into two
subgroups: MCI patients who have converted to AD (MCI
converters, MCIc), and MCI patients who have not converted to
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21AD (MCI non-converters, MCInc). Different modalities of disease
indicators have been studied for AD progression including
neuroimaging biomarkers [1,2,3,4,5], biomedical biomarkers [6],
and neuropsychological assessments [7,8,9]. Structural magnetic
resonance imaging (MRI) captures disease-related structural
patterns by measuring loss of brain volume and decreases in
cortical thickness. A number of studies, covering region of interest
(ROI), volume of interest, voxel-based morphometry and shape
analysis, have reported that the degree of atrophy in several brain
regions, such as the hippocampus, entorhinal cortex and medial
temporal cortex, are sensitive to disease progression and predict
MCI conversion [10,11,12,13,14,15]. Biochemical changes in the
brain are reflected in the cerebrospinal fluid (CSF). CSF con-
centrations of total tau (t-tau), amyloid-b 1 to 42 peptide (Ab1–42)
and tau phosphorylated at the threonine 181 (p-tau181p) are
considered to be CSF biomarkers which are diagnostic for AD
[6,16,17]. An increase in levels of CSF t-tau and a decline in Ab1–
42 have been identified as being amongst the most promising and
informative AD biomarkers [6,18]. Neuropsychological assess-
ments are potentially useful for disease prognosis. Some cogni-
tive measurements have shown statistically significant differences
between MCI progressors and nonprogressors over the course of
12 months [19].
While most research focuses on a single modality of data,
different modalities of data may provide complementary informa-
tion. A recent study showed that a combination of MRI, CSF
and fluorodeoxyglucose positron emission tomography (FDG-
PET) predicted MCI converters within 18 months with a sensi-
tivity of 91.5% and a specificity of 73.4% (total 99 individuals)
[20]. Davatzikos and colleagues analyzed MRI and CSF bio-
markers and correctly classified 55.8% (sensitivity, 94.7%; speci-
ficity, 37.8%) of 239 individuals as either MCIc or MCInc using
SPARE-AD (Spatial Pattern of Abnormalities for Recognition of
Early AD) index [15]. Ewers et al. [21] obtained accuracies from
64% to 68.5% for 130 MCI participants with different markers:
MRI, CSF, neuropsychological tests, and their combinations.
Although significant progress has been made, most investiga-
tions concerning MCI prediction have chosen features based on
prior knowledge and findings. To the best of our knowledge, few
publications have selected the most relevant features automati-
cally, thereby eliminating the scope for redundancy in MCI pre-
diction. In this study, using an Alzheimer’s Disease Neuroimaging
Initiative (ADNI) dataset, we employed data-driven techniques
and examined single and multiple modalities of features to capture
MCI conversion within 24 months; we also analyzed conversion
time. Firstly, structural measures of each ROI were extracted
using FreeSurfer; CSF biomarkers and neuropsychological and
functional measures (NMs) were downloaded from the ADNI
website. Secondly, feature selection was performed on three moda-
lities of features, respectively, in order to select optimal feature
subsets. Finally, support vector machine (SVM) classifiers were
trained to classify MCI individuals using selected features. Training
was conducted on baseline normal control (NC) and AD groups,
and testing was conducted on the baseline MCI group. Our
hypothesis was that there could be symptoms of brain structural and
functional deficits in the MCIc group, but not (much) in MCInc
group, which could be identified at baseline. Previous research
about spatial patterns of brain atrophy has demonstrated that
characteristics of the MCIc group almost entirely overlap with those
of AD individuals, and MCInc group characteristics almost entirely
overlap with those of NC individuals [22]. Additionally, studies by
Fan et al. [22], Costafreda et al. [10] and McEvoy et al. [13]
successfully predicted MCIc using classifiers constructed from NC
and AD participants, suggesting our hypothesis was convincing.
Theoretically, classifiers constructed on MCI individuals should be
able to separate MCIc/MCInc accurately; however, the follow-up
of24monthsis not sufficient toobtaingroundtruth labels ofMCIc/
MCInc, which can only be achieved a much longer time-frame. In
ourstudy,some MCIncparticipantsconverted after 24months,and
the use of MCI participants for model generation may result in high
training errors. For these reasons classifiers were constructed on NC
and AD participants, and then applied to MCI individuals. We
hypothesized that the combination of different modes of data would
achieve better results because each modality separately produces
a limited prediction. On the other hand, cross-sectional baseline
differences between MCInc and MCIc would be most like NC and
AD, respectively. In other words, the individuals with MCI who are
about to develop AD would appear more similar to AD, whereas
those who will not convert to AD would appear more similar to NC
within selected features.
Materials and Methods
Ethics
For the purpose of this study we used ADNI data that were
previously collected across 50 sites. Study subjects gave written
informed consent at the time of enrollment for data collection and
completed questionnaires approved by each participating site’s
Institutional Review Board (IRB), including Albany Medical
College, Banner Alzheimer’s Institute and Baylor College of
Medicine etc. The complete list of ADNI sites’ IRBs can be found
at the link: http://adni.loni.ucla.edu/about/data-statistics/, or in
Text S1.
Participants
Data used in the preparation of this article were obtained from
the ADNI database (www.loni.ucla.edu/ADNI) in April 2010.
The ADNI was launched in 2003 by the National Institute on
Aging, the National Institute of Biomedical Imaging and Bioen-
gineering, the Food and Drug Administration, private pharma-
ceutical companies and non-profit organizations, as a $US60
million, 5-year public–private partnership. The primary goal of
the ADNI has been to test whether serial MRI, positron emission
tomography (PET), other biological markers, and cognitive and
neuropsychological assessment can be combined to measure the
progression of MCI and early AD. Determination of sensitive and
specific markers of very early AD progression is intended to aid
researchers and clinicians to develop new treatments and monitor
their effectiveness, as well as lessen the time and cost of clinical
trials. For up-to-date information, please refer to: http://www.
adni-info.org.
The eligibility criteria for the inclusion of participants are
described at: http://www.adni-info.org/Scientists/ADNIGrant/
ProtocolSummary.aspx. General inclusion/exclusion criteria are
as follows: normal subjects had Mini-Mental State Examination
(MMSE) [23] scores between 24 and 30 (inclusive), a Clinical
Dementia Rating (CDR) [24] of 0, and were non depressed, non
MCI, and non demented. MCI patients had MMSE scores
between 24 and 30 (inclusive), a memory complaint, had objective
memory loss measured by education adjusted scores on the
Wechsler Memory Scale Logical Memory II [25], a CDR of 0.5,
absence of significant levels of impairment in other cognitive
domains, essentially preserved activities of daily living, and an
absence of dementia. AD patients had MMSE scores between 20
and 26 (inclusive), a CDR of 0.5 or 1.0, and met NINCDS/
ADRDA [26] criteria for probable AD.
Only ADNI subjects who had pre-processed and quality
checked MR images, baseline CSF measurements and at least
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yielded a total of 87 MCInc, 56 MCIc, 111 NC and 96 AD
patients. Table 1 provides detailed participant demographics infor-
mation for training data and test data. There were no significant
differences between NC and AD, MCInc and MCIc groups in
terms of age and sex. We focused on baseline classification of MCI
individuals, therefore MRI scans, CSF biomarkers, demographic
information and neuropsychological data were all obtained at the
baseline visit.
MRI imaging acquisition
Structural MRI scans were acquired from 1.5T scanners at
multiple sites across the United States and Canada. MRI protocols
ensured comparability across a variety of scanners (GE, Siemens
or Philips). The imaging sequence was a 3-dimentional sagittal
magnetization prepared rapid gradient-echo (MPRAGE). The
MPRAGE sequence was repeated back-to-back to increase the
likelihood of acquiring at least one good quality MPRAGE scan.
In addition, a dual fast spin-echo (proton density/T2-weighted)
sequence was acquired to evaluate the presence or state of vascu-
lar disease and general pathology detection [27,28]. The pre-
processing correction procedure was as follows: (1) grad warp
correction of image geometry distortion due to gradient non-
linearity; (2) B1 non-uniformity processing to correct the image
intensity non-uniformity; and (3) N3 processing to reduce residual
intensity non-uniformity [28]. Original scans and pre-processed
images are available at http://adni.loni.ucla.edu/.
Overview of prediction procedure
The prediction procedure consisted of three processing stages:
feature extraction and collection, optimal feature subset selection,
and classification. Figure 1 illustrates the diagram of the prediction
framework. During the training stage, MRI features which had
been extracted automatically using FreeSurfer, as well as a set of
NM and CSF biomarkers, were downloaded from the ADNI
website. A feature selection method was then employed to choose
optimal subsets of features, respectively. After feature selection, we
combined multiple features, including the MRI, NM and CSF
features to train classifiers to distinguish between NC and AD. In
the testing stage, we extracted what we had determined to be the
optimal feature subsets during the training stage. A predictive
value was then generated for each test subject through the SVM
classifier.
MRI feature extraction
Advances in MR image analysis algorithms have led to the
development of automated parcellation tools which can segment
the whole brain into anatomic regions and quantify the features of
each region [29]. The widely used FreeSurfer software package
(http://surfer.nmr.mgh.harvard.edu/) was applied to each partic-
ipant’s pre-processed scan. Processing results using FreeSurfer
Version 4.3.0 have been published on the website: www.loni.ucla.
edu/ADNI. Briefly, the processing included automated Talairach
space transformation, intensity inhomogeneity correction, removal
of non-brain tissues, intensity normalization, tissue segmentation
(the subcortical structures, brain stem, cerebellum, and cerebral
cortex) [30,31], automated correction of topology defects, surface
deformation to form the gray/white matter boundary and gray
matter/CSF boundary [32], and parcellation of the cerebral
cortex [33]. The atlas used, detailed in [33], included 34 cortical
ROIs per hemisphere. For each ROI, the cortical thickness
average (TA), standard deviation of thickness (TS), surface area
(SA) and cortical volume (CV) were calculated as features. SA was
calculated as the area of the surface layer equidistant between the
gray/white matter and gray matter/CSF surfaces. CV at each
vertex over the whole cortex was computed by the product of the
SA and thickness at each surface vertex. Left and right hemisphere
SA and total intracranial volume (ICV) were also included. For
each subcortical structure, the subcortical volume (SV) was
extracted. This yielded a total of 323 MRI features including
279 cortical and 44 subcortical features (see Table S1).
CSF biomarker collection
Baseline CSF samples were obtained through lumbar punc-
ture at all participating sites. The CSF collection and transpor-
tation protocols and details on CSF are described in [6] and
on the ADNI website (http://www.adni-info.org/Scientists/
ADNIScientistsHome.aspx). CSF concentrations of t-tau, Ab1–42
and p-tau181p were measured, as were ratios of t-tau to Ab1–42,a n d
p-tau181p to Ab1–42. CSF features for subjects taken at baseline are
listed in Table 2.
NM collection
NMs were undertaken at the time of scan acquisition as shown
in Table 3. Neuropsychological tests used in this study include
Logical Memory II (LM) [25], Auditory Verbal Learning Test
(AVLT) [34], category fluency and digit span, Trail Making Tests
Table 1. Participant demographic characteristics.
Training data Test data
NC (n=111) AD (n=96) p
a MCInc (n=87) MCIc (n=56) p
b
Age 75.465.12 74.868.01 0.454 74.366.98 75.0267.49 0.585
Male (%) 50.5 58.3 0.256 63.2 67.9 0.570
Education (years) 15.762.81 15.263.35 0.196 16.462.74 15.463.11 0.042
ApoE e4 carriers (%) 23.4 69.8 ,0.001 47.1 64.3 0.045
MMSE 29.0761.0 23.5161.9 ,0.001 27.1361.7 26.5761.9 0.066
CDR 0600 . 7 60.25 ,0.001 0.560 0.560— —
Note: Values are mean 6 SD unless otherwise indicated. NC, normal control; AD, Alzheimer’s Disease; MCInc, mild cognitive impairment patients who have not
converted to AD within 24 months; MCIc, mild cognitive impairment patients who have converted to AD within 24 months; ApoE, apolipoprotein E; MMSE, Mini-Mental
State Examination; CDR, Clinical Dementia Rating.
aTwo sample t-test for all comparisons between NC and AD groups except sex and ApoE e4 carriers, where Pearson’s chi-square tests were used.
bTwo sample t-test for all comparisons between MCInc and MCIc groups except sex and ApoE e4 carriers, where Pearson’s chi-square tests were used.
doi:10.1371/journal.pone.0021896.t001
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The Functional Assessment Questionnaire (FAQ) [38] was used
for functional testing. Details of ADNI NMs are available at
(http://adni.loni.ucla.edu/wp-content/uploads/2010/09/BLCog
TestingWorksheet.pdf) and on the ADNI cognitive testing web-
page: http://www.adni-info.org/Scientists/CognitiveTesting.aspx.
Feature selection
Of the pool of available features, some were sensitive and rele-
vant to AD and some were less relevant or redundant for classi-
fication. We therefore performed a feature selection procedure in
NC and AD groups in order to identify the most characteristic
structural AD-like patterns which could be looked for in MCInc
and MCIc individuals. The approach applied for MRI and CSF
features is a filter followed by a wrapper method, while we used a
filter for NM feature selection.
MRI and CSF feature selection. An optimal feature subset
is achieved by selecting the most relevant features and eliminating
redundant features. Feature ranking followed by a wrapper me-
thod is accepted as a recommended part of a feature selection
procedure [39]. Feature ranking evaluates all of the features by
looking at the intrinsic characteristics of the data with respect to
clinical evaluations. Wrapper methods evaluate the effectiveness
of a subset by the accuracy (or AUC) of its classification. We
performed the same feature selection approach for MRI and CSF
features. During the feature ranking stage, we first linearly
normalized all the features to the range between 0 and 1, since
features have different scales. We then employed the minimum
redundancy and maximum relevance (mRMR) filter method
introduced by Peng et al. [40,41]. This method computes the
mutual information of two variables by their probabilistic density
function. The mRMR feature ranking is obtained by optimizing
two criteria, i.e., maximum relevance and minimum redundancy,
simultaneously. The detailed implementation algorithm is de-
scribed in [40,41]. In order to select the optimal feature subset
after feature ranking, we employed the popular classifier SVM by
incrementally adding features based on their ranking (highest to
lowest). Optimal features were selected when the highest AUC was
obtained. We performed 10-fold cross-validation and repeated the
procedure 20 times with training samples in order to identify
robust and stable discriminative features. Selection frequency was
computed by dividing the number of selection by the total num-
ber of times the procedure was repeated. The higher the selec-
tion frequency, the more stable and reliable the feature is for
discrimination. In order to identify the most discriminative fea-
ture subset, we selected features with over 50% selection fre-
quency. This yielded a subset of 7 features out of a possible 323
MRI features, and a subset of 2 features out of 5 CSF biomarkers.
NM feature selection. Our neuropsychological feature
selection was performed using a filter method. A wrapper was not
Figure 1. Overview of the prediction procedure.
doi:10.1371/journal.pone.0021896.g001
Table 2. Baseline CSF biomarker concentrations and ratios of subjects.
t-tau(pg/ml) Ab1–42 (pg/ml) p-tau181p (pg/ml) t-tau/Ab1–42 p-tau181p/Ab1–42
NC (n=111) 69.8630.6 205.6655.6 24.9614.6 0.3960.3 0.1460.1
AD (n=96) 122.9658.0 142.8640.0 42.2620.1 0.9360.5 0.3260.2
MCInc (n=87) 96.1653.2 163.6658.5 34.3617.1 0.7260.6 0.2660.2
MCIc (n=56) 110.5645.1 142.2635.9 39.5615.5 0.8260.3 0.3060.1
Note: Values are mean 6 SD. NC, normal control; AD, Alzheimer’s Disease; MCInc, mild cognitive impairment patients who have not converted to AD within 24 months;
MCIc, mild cognitive impairment patients who have converted to AD within 24 months; CSF, cerebrospinal fluid; t-tau, total tau; p-tau181p, tau phosphorylated at the
threonine 181; Ab1–42, amyloid-b 1 to 42 peptide.
doi:10.1371/journal.pone.0021896.t002
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groups. If a wrapper were to be used, the highest accuracy would be
achieved when using the top ranked feature. Therefore, only one
feature can be selected in NC and AD groups, whereas this feature
may be not an optimal subset for MCI classification. Therefore we
filtered neuropsychological features based on two rankings: the
maximal relevance method which ranked features based on mutual
information between each feature and corresponding clinical labels
[41], and the AUC values in SVM classification of each individual
NM to discriminate between NC and AD. Note that linear feature
normalization was applied before ranking. In order to reduce
variability, we carried out two feature ranking schemes 20 times
using 10-fold cross-validation on the training set.
Classification using SVM
SVM is a powerful, supervised, classification algorithm for
pattern classification that uses a kernel function to construct linear
classification boundaries in high (often infinite) dimensional spaces
[42]. It is widely accepted as one of the most powerful classifiers
available. In SVM, the output in a linearly separable case has the
form
f(x)~wTxzb
where x is an input vector.
For a given hyperplane (decision surface) described with the
equation wTxzb~0, and for a vector z that does not belong to
the hyperplane, the following is satisfied [42,43]:
wTzzb~+d w kk
where d is the ‘‘distance’’ of the ‘‘point’’ z to the given hyperplane.
Therefore the output f(x) (i.e. predictive value) of the SVM is
Table 3. Baseline neuropsychological and functional measures.
Assortment variable NC (n=111) AD (n=96) MCInc (n=87) MCIc (n=56)
LM delayed recall 12.663.6 1.161.8 4.362.7 2.862.3
LM immediate recall 13.563.6 3.962.9 7.562.5 6.063.0
Boston Naming Test 27.562.4 23.166.1 25.864.1 25.763.7
AVLT trials 1–5 43.368.4 23.467.1 32.868.9 26.666.7
AVLT delayed recall 7.363.5 162.0 3.363.4 1.561.9
AVLT delayed recall/trial 5 (%) 66.5630.0 14.2625.0 35.2630.6 21.1626.7
Category fluency (vegetable) 14.463.8 8.163.4 11.163.5 10.163.1
Category fluency (animal) 19.365.7 12.864.9 16.364.8 15.664.8
Trail Making Test A, s 36.7613.5 68.4638.7 42.6620.6 49.6627.2
Trail Making Test B, s 88.5641.5 204.3686.7 118.2663.2 144.6671.2
Clock drawing 4.660.7 3.361.3 4.360.9 3.861.2
Digit forwards 8.762.1 7.861.9 8.162.1 8.561.9
Digit backwards 7.062.2 4.961.8 6.362.0 6.261.7
FAQ 0.260.7 12.766.7 2.863.9 5.264.4
Note: Values are mean 6 SD. NC, normal control; AD, Alzheimer’s Disease; MCInc, mild cognitive impairment patients who have not converted to AD within 24 months;
MCIc, mild cognitive impairment patients who have converted to AD within 24 months; LM, logical memory II; AVLT, Auditory Verbal Learning Test; FAQ, Functional
Assessment Questionnaire.
doi:10.1371/journal.pone.0021896.t003
Table 4. Selected MRI features.
Ranking Selection frequency (%) Feature Type NC vs. AD MCInc vs. MCIc
p Corr. p
a p Corr. p
a
1 91.50 Entorhinal Cortex L TA ,0.0001 ,0.0001 0.1735 1.0
2 88.50 Middle Temporal Gyrus R CV ,0.0001 ,0.0001 0.0008 0.0056
3 71.00 Hippocampus R SV ,0.0001 ,0.0001 0.0015 0.0105
4 65.50 Hippocampus L SV ,0.0001 ,0.0001 0.0063 0.0441
5 60.00 Inferior Parietal Cortex R TA ,0.0001 ,0.0001 0.0008 0.0056
6 59.00 Retrosplenial Cortex L TA ,0.0001 ,0.0001 0.0222 0.1554
7 53.00 Middle Temporal Gyrus L TA ,0.0001 ,0.0001 0.0012 0.0084
Note: NC, normal control; AD, Alzheimer’s disease; MCInc, mild cognitive impairment patients who have not converted to AD within 24 months; MCIc, mild cognitive
impairment patients who have converted to AD within 24 months; CV, cortical volume; TA, cortical thickness average; SV, subcortical volume; L, left hemisphere; R, right
hemisphere.
aBonferroni-corrected (Corr.) p values are shown after controlling for multiple comparisons, with significant differences in bold (Corr. p,0.05).
doi:10.1371/journal.pone.0021896.t004
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from the chosen hyperplane. In a non-linear case, we still look for
a linear separation hyperplane within the mapped feature space.
For each MCI participant, the classifier generated a continuous
predictive value, which was then forced to be either positive
(MCIc) or negative (MCInc) using threshold decision rules. The
relationship between predictive values and conversion time was
then analyzed. In the present study, SVM classifiers were imple-
mented using the LIBSVM toolbox [44] with the Gaussian radial
basis function (RBF) kernel, i.e. K(xi,xj)~exp({c xi{xj
   2),
cw0. Unlike the linear kernel, the RBF kernel can handle cases
where the relationship between clinical labels and features are
nonlinear [45]. The parameters, C (a constant determining the
tradeoff between training error and model flatness) and c
(Gaussian kernel width) were optimized via cross-validation on
the training data. Note that, as different features had different
scales, we linearly scaled each training feature to conform to a
range between 0 and 1; the same scaling method was sub-
sequently applied to the test data.
Results
Discriminating MRI, CSF and NM features
Optimal MRI and CSF feature subsets are summarized in
Table 4 and Table 5. For selected MRI features, the subcortical
region was the hippocampus and the cortical regions included
the entorhinal cortex, middle temporal gyrus, inferior parietal
cortex and retrosplenial cortex. The thickness of the left
entorhinal cortex was the highest ranked with 91.50% selection
frequency. The volume of the right middle temporal gyrus was
ranked second with 88.50% selection frequency. Volumes of the
right and left hippocampus were also important features ranking
third and fourth, respectively, followed by the thickness of the
right inferior parietal cortex, left retrosplenial cortex and left
middle temporal gyrus. t-tests of the 7 features showed statis-
tically significant differences between NC and AD groups. Mean-
while, t-tests of MCInc and MCIc groups showed significant
differences, with the exception of average thickness of the left
entorhinal cortex and retrosplenialcortex. ForCSF features,t-tau/
Ab1–42 and p-tau181p/Ab1–42 were selected. There were significant
differences between NC and AD subjects, but no significant
differences found between MCInc and MCIc individuals (see
Table 5).
The rankings of 14 NM features based on two schemes are
presented in Table 6. We chose measures with a correlation
coefficient above 0.3 and classification AUC above 0.95 in order
to select the most discriminate features. 5 NM features were
selected, including FAQ, LM delayed recall, LM immediate recall,
AVLT delayed recall and AVLT trials 1–5 (see Table 7). Statistical
analysis showed all of the selected features to be significantly
different between NC and AD, and between MCInc and MCIc
groups.
Table 5. Selected CSF features.
Ranking Selection frequency (%) Feature NC vs. AD MCInc vs. MCIc
p Corr. p
a p Corr. p
a
1 94.5% t-tau/Ab1–42 ,0.0001 ,0.0001 0.2894 0.5788
2 56.5% p-tau181p/Ab1–42 ,0.0001 ,0.0001 0.1351 0.2702
Note: NC, normal control; AD, Alzheimer’s disease; MCInc, mild cognitive impairment patients who have not converted to AD within 24 months; MCIc, mild cognitive
impairment patients who have converted to AD within 24 months; t-tau, total tau; Ab1–42, amyloid-b 1 to 42 peptide; p-tau181p, tau phosphorylated at the threonine 181.
aBonferroni-corrected (Corr.) p values are shown after controlling for multiple comparisons, with significant differences in bold (Corr. p,0.05).
doi:10.1371/journal.pone.0021896.t005
Table 6. Neuropsychological feature ranking.
Ranking 1 Correlation coefficient Ranking 2 Classification AUC Neuropsychological and functional test
1 0.4832 2 0.9889 FAQ
2 0.4742 1 0.9990 LM delayed recall
3 0.3832 3 0.9794 LM immediate recall
4 0.3219 5 0.9576 AVLT delayed recall
5 0.3160 4 0.9685 AVLT trials 1–5
6 0.2741 6 0.9211 AVLT delayed recall/trial 5
7 0.2594 9 0.8677 Trail Making Test B
8 0.2392 7 0.9068 Category fluency (vegetable)
9 0.1973 12 0.8015 Trail Making Test A
10 0.1917 8 0.8976 Clock drawing
11 0.1560 10 0.8275 Category fluency (animal)
12 0.1176 13 0.7730 Boston Naming Test
13 0.1074 11 0.8236 Digit backwards
14 0.0384 14 0.6588 Digit forwards
Note: FAQ, Functional Assessment Questionnaire; LM, logical memory II; AVLT, Auditory Verbal Learning Test.
doi:10.1371/journal.pone.0021896.t006
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modalities of features
We trained SVM classifiers using selected NM, MRI and CSF
measures to discriminate between NC and AD participants, and
tested on MCI participants. As shown in Table 8, NM method
achieved a good AUC (0.761), for which it outperforms individual
MRI (0.650) and CSF (0.641) method. Combining NM and CSF/
MRI features increased the classification performance. The best
performance was achieved using a combination of three modalities
of features, i.e., NM, CSF and MRI, which had an accuracy of
67.13%, a sensitivity of 96.43%, a specificity of 48.28%, and an
AUC of 0.796.
During the testing stage, the classifier generated a predictive
value for each subject. Most MCIc subjects have negative pre-
dictive values which indicated the majority had been classified
correctly (96.43%); while MCInc subjects have a wider range of
predictive values from negative to positive values (see Figure 2).
Further analysis of the predictive values at different conversion
times using selected NM, MRI and CSF features is presented in
Figure 3 and Figure 4. Specifically, MCIc subjects who converted
at 6 months, 12 months, 18 months and 24 months are
21.0760.35, 20.8860.29, 20.6560.34, and 20.6660.42, res-
pectively. Predictive values of MCIc subjects who converted within
12 months and after 12 months (before 24 months) are
20.9260.31 and 20.6660.38, respectively, which were signifi-
cantly different (p,0.01, Figure 4).
Discussion
Te present study examined the capability of single and mul-
tiplemodalitiesofpredictorstoidentifyconversion fromMCItoAD
using pattern classification techniques. We used a feature selection
approach and selected optimal feature subsets from different
modalities. In addition, prediction of conversion time was investi-
gated through the predictive values at different conversion times.
Single mode predictors
Feature selection from MRI features provided a subset of dis-
criminating structural measures. Our data-driven method showed
that spatial atrophy predictors of MCI conversion included ROIs
of the entorhinal cortex, inferior parietal cortex, retrosplenial
cortex, middle temporal gyrus and hippocampus. Our results cor-
respond with a number of previous studies showing that atrophy in
these structures has been found to be predictive during disease
progression. [1,21,29,46,47,48]. These ROIs are from the episodic
memory network and they served as the strongest predictors of
memory performance, reflecting the association between regional
atrophy and loss of memory [49,50]. The entorhinal cortex and
hippocampus atrophies are established imaging AD biomarkers
[51]; both contribute to prediction [21,47,48]. Moreover, the
entorhinal cortex and inferior parietal lobule are important pre-
dictors of time to progression [46]. In addition, we found the
entorhinal cortex was the highest ranked of other morphometry
features, even superior to hippocampus volumes. This is consistent
with findings from previous studies [46,47,48]. t-tau/Ab1–42 and
p-tau181p/Ab1–42 are the most sensitive predictors in the early
diagnosis of AD. They both increase sensitivity in prognosis. Some
studies [6,52] have reported similar results.
Statistically significant differences between NC and AD groups
illustrate that the selected MRI and CSF features were highly
discriminative. The t-test conducted on evaluation results from
MCInc and MCIc subjects showed that most features were sta-
tistically significant. This suggests that the trends involving features
which discriminate between NC and AD may also distinguish
between MCInc and MCIc subjects. Although the entorhinal
cortex, t-tau/Ab1–42 and p-tau181p/Ab1–42 were not significantly
different,ourresultsindicated that they wereindispensable since the
combination of features performed better, suggesting that these
features are mutually complementary and that their combination
works as a good classificatory predictor. An additional factor
concerned short-term follow-ups. These influence labels of MCInc
and we found that subjects changed from MCInc to MCIc when
evaluations were provided over a longer period of time.
Table 7. Selected NM features.
Ranking Feature NC vs. AD MCInc vs. MCIc
p Corr. p
a p Corr. p
a
1F A Q ,0.0001 ,0.0001 0.00082 0.0041
2 LM delayed recall ,0.0001 ,0.0001 0.00078 0.0039
3 LM immediate recall ,0.0001 ,0.0001 0.00188 0.0094
4 AVLT delayed recall ,0.0001 ,0.0001 0.00031 0.0016
5 AVLT trials 1–5 ,0.0001 ,0.0001 0.00002 0.0001
Note: NC, normal control; AD, Alzheimer’s disease; MCInc, mild cognitive impairment patients who have not converted to AD within 24 months; MCIc, mild cognitive
impairment patients who have converted to AD within 24 months; NM, neuropsychological and functional measure; LM, logical memory II; AVLT, Auditory Verbal
Learning Test; FAQ, Functional Assessment Questionnaire.
aBonferroni-corrected (Corr.) p values are shown after controlling for multiple comparisons, with significant differences in bold (Corr. p,0.05).
doi:10.1371/journal.pone.0021896.t007
Table 8. Classification of MCIc versus MCInc at baseline.
Method Accuracy (%) Sensitivity (%) Specificity (%) AUC
NM, CSF, MRI 67.13 96.43 48.28 0.796
NM, CSF 65.04 94.64 45.98 0.784
NM, MRI 62.24 92.86 42.53 0.781
NM 65.04 91.07 48.28 0.761
MRI, CSF 58.74 71.43 50.57 0.673
MRI 62.24 57.14 65.52 0.650
CSF 60.84 80.36 48.28 0.641
Note: AUC, area under the receiver operating characteristic curve; MRI
represents 7 selected structural features; NM represent 5 selected
neuropsychological and functional measures; CSF represents 2 selected CSF
features.
doi:10.1371/journal.pone.0021896.t008
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cognition from MCI to AD [7,8]. Neuropsychological measures
(either alone or combined with other predictors) are being widely
investigated to predict which individuals progress to AD and
which do not [7,8,21,53]. MCIc/MCInc were labelled by both
baseline and follow-up diagnoses, which required clinical exam-
ination and comprehensive neuropsychological assessments, there-
fore NM could be biased compared with MRI and CSF measures.
Our results also indicated that NM achieved better prediction
performance. Our findings of NM predictors included 5 features,
which are significantly different between NC and AD groups, and
between MCInc and MCIc groups. Classification performance for
the use of all 14 NM features was comparable with the use of 5
selected features, suggesting our approach with feature selection is
effective since simple and relatively fewer markers might make
prediction more practical. We found that LM delayed recall was
especially sensitive in distinguishing between MCInc and MCIc
groups. This is consistent with related research which has shown
that this test has typically greater power (highest loading) in
predicting conversion to AD [7,9,54]. While relatively few studies
have included functional measures in the detection of MCI con-
version, our findings indicated that inclusion of FAQ scores was
important for achieving a sensitive indicator of disease progression.
Multivariate predictors
NMs outperformed FreeSurfer-derived MRI and CSF features
and attained a good AUC. However, multimodal feature com-
bination appears more promising. The combination of NM, MRI
and CSF features outperformed any single modality of data. The
high sensitivity suggests this combination may be a good pre-
dictor for prognosis of MCI. Our results marginally outperformed
Davatzikos et al.’s state-of-the-art study [15] in terms of accuracy,
sensitivity, specificity and AUC. Our results are consistent with
Figure 2. The histograms of SVM predictive values of MCInc (left) and MCIc (right).
doi:10.1371/journal.pone.0021896.g002
Figure 3. Predictive values of MCIc at different conversion
time. Predictive values of MCIc at 6-month (21.0760.35), 12-month
(20.8860.29), 18-month (20.6560.34) and 24-month (20.6660.42)
follow-up evaluations.
doi:10.1371/journal.pone.0021896.g003
Figure 4. Predictive values of MCIc at different conversion
time. Predictive values of MCIc within 12-month (20.9260.31) and
after 12-month (20.6660.38) follow-up evaluations. *Significant
differences between predictive values of conversion time within 12
months and after 12 months (p,0.01).
doi:10.1371/journal.pone.0021896.g004
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while MCInc had mixed markers, suggesting that some MCInc
participants may convert later [15]. For example, in our study, 10
MCInc subjects had 36-month follow-ups. We found our classifier
was able to detect 8 (80%) of them as converters, suggesting longer
follow-up will clarify the specificity of baseline measures. We note
that our accuracy is higher than Zhang et al.’s study, which used
the combination of MRI, CSF and PET data [20], although our
specificity is lower. In terms of accuracy, our method is com-
parable to Ewers et al.’s study, which used logistic regression and
picked up features by prior knowledge [21]. It is problematic to
compare classification results from studies using different popula-
tions, therefore we only compared our results with the studies
using ADNI cohorts.
Taken together, MRI measures offer information regarding the
structural degeneration of AD, CSF biomedical levels correspond
with the pathological changes at the biological level, and NMs
reflect the memory deficits and behavioral symptoms of AD. Of
the three modalities of data, NMs are the most distinguishing, and
MRI and CSF data provide complementary predictive informa-
tion, which enhanced prediction performance and prognostic
power overall. The optimal combination of these multimodal
features would therefore enable greater insight into the disease, as
they provide complementary information about AD progression.
While it is challenging to predict conversion time, it is highly
significant for clinical diagnosis. In our study, MCI converters who
converted within 12 months of follow-up have AD-like patterns;
hence their predictive values are lower. Predictive values for
MCI subjects who converted after 12 months are generally higher.
Therefore our methodology appears to be a useful means for
predicting conversion time.
Limitations
Our study has some limitations. Firstly, we did not use weigh-
tings for different modalities when we combined them. Zhang et
al.’s approach of using different weightings may improve the
prediction performance of our method [20]. Another limitation is
the relatively short interval of 24-month follow-up. A longer
follow-up interval for MCInc subjects would make the ground
truth labels more reliable because some MCI subjects may convert
later. Accordingly, prediction specificity and accuracy could be
better validated.
Conclusions
The present study proposed multivariate predictors for tracking
AD progression using pattern classification techniques. Multimod-
al features were combined after feature selection from structural
MRI, CSF and NM measures. Classification results verify our
hypothesis that the combination of multimodal features, including
NM, MRI and CSF, outperforms a single modality of features,
possibly because different features are mutually complementary.
Our proposed multivariate predictors achieved good baseline
accuracy and high sensitivity. In addition, predictive values of
MCIc within 12 months and after 12 months are significantly
different. Furthermore, the selected features have proved to be
closely related to AD progression, which corresponds with the
findings of recent studies and verifies the effectiveness of our
feature selection method. In summary, our prediction procedure
may be practical and helpful for clinical diagnosis.
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